{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:42:37Z","timestamp":1787010157958,"version":"build-2736575974"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"16","license":[{"start":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:00:00Z","timestamp":1619136000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"CAMS Innovation Fund for Medical Science","award":["2019TX310002"],"award-info":[{"award-number":["2019TX310002"]}]},{"name":"National Guided Science and Technology Development Project of Sichuan Province","award":["2020ZYD009"],"award-info":[{"award-number":["2020ZYD009"]}]},{"name":"the Science and Technology Project of Chengdu","award":["2017-CY02-00030-GX"],"award-info":[{"award-number":["2017-CY02-00030-GX"]}]},{"name":"Postdoctoral Program of West China Hospital, Sichuan University","award":["2020HXBH084"],"award-info":[{"award-number":["2020HXBH084"]}]},{"name":"Grant of Innovative Research Project for College Students, Sichuan University, Ministry of Education","award":["C2021116604"],"award-info":[{"award-number":["C2021116604"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Coronavirus disease 2019 (COVID-19) has spread almost all regions of the world and caused great loss to the whole body of mankind. Thus, numerous clinical trials were conducted to find specific medicine for COVID-19 recently. However, it remains unanswered whether they are beneficial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This study aimed to evaluate the efficiency and safety of the COVID-19 medicine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Studies were determined through searching PubMed, Embase, Cochrane Library, and Medline. The studies of COVID-19 medicine were involved with eligible end points containing mortality, discharge rate, rate of clinical improvement, and rate of serious adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 33 studies involving 37,879 patients were included in our study, whose intervening measures contained three major types of COVID-19 medicine, ACEI\/ARB, antiviral medicine, and chloroquine\/hydroxychloroquine. Compared to control group, COVID-19 drugs have no distinct effect on mortality (RR, 0.93; 95% CI, 0.79\u20131.11,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a.43) and discharge rate (RR, 1.06; 95% CI, 0.98\u20131.14,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a.13). However, antiviral medicine presents the obvious advantage in clinical improvement (RR, 1.11; 95% CI, 1.01\u20131.23,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&lt;\u200a.05). In addition, the serious adverse events rate (RR, 0.75; 95% CI, 0.63\u20130.88,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&lt;\u200a.05) of COVID-19 medicine is lower than control group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The results indicated antiviral medicine was potential specific medicine for COVID-19 treatment by improving clinical symptoms, but it failed to increase the discharge rate and reduce mortality. Chloroquine\/hydroxychloroquine and ACEI\/ARB had no significant effect on treatment of COVID-19, thus they were not recommended for routine medication. Moreover, more trials are needed to find effective drugs to lower the mortality of COVID-19 patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000025532","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T09:23:26Z","timestamp":1618997006000},"page":"e25532","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["The therapeutic effect and safety of the drugs for COVID-19"],"prefix":"10.1097","volume":"100","author":[{"given":"Rong","family":"Qiu","sequence":"first","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine"},{"name":"West China Medical School\/West China Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Xiao","sequence":"additional","affiliation":[{"name":"West China School\/Hospital of Stomatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Gao","sequence":"additional","affiliation":[{"name":"West China Medical School\/West China Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihang","family":"Weng","sequence":"additional","affiliation":[{"name":"West China School\/Hospital of Stomatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiran","family":"Zhang","sequence":"additional","affiliation":[{"name":"West China Medical School\/West China Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengdi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanlin","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,4,23]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","article-title":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia","volume":"382","author":"Li","year":"2020","journal-title":"N Engl J Med"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1056\/NEJMoa2005412","article-title":"Epidemiology of Covid-19 in a long-term care facility in King County, Washington","volume":"382","author":"McMichael","year":"2020","journal-title":"N Engl J Med"},{"key":"R5-20250504","first-page":"1849","article-title":"Training and fit testing of health care personnel for reusable elastomeric half-mask respirators compared with disposable N95 respirators","volume":"323","author":"Pompeii","year":"2020","journal-title":"JAMA"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1001\/jama.2020.2783","article-title":"Positive RT-PCR test results in patients recovered from COVID-19","volume":"323","author":"Lan","year":"2020","journal-title":"JAMA"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet (London, England)"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1126\/science.abb7498","article-title":"Structure of the RNA-dependent RNA polymerase from COVID-19 virus","volume":"368","author":"Gao","year":"2020","journal-title":"Science"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1001\/jama.2020.11301","article-title":"Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality","volume":"324","author":"Fosbol","year":"2020","journal-title":"JAMA"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe Covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N Engl J Med"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"e208857","DOI":"10.1001\/jamanetworkopen.2020.8857","article-title":"Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial","volume":"3","author":"Borba","year":"2020","journal-title":"JAMA Netw Open"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci Trends"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ (Clinical Research ed)"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1258\/1355819021927674","article-title":"Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice","volume":"7","author":"Higgins","year":"2002","journal-title":"J Health Serv Res Policy"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clinical Research ed)"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/ajh\/hpaa096","article-title":"Use of RAAS inhibitors and risk of clinical deterioration in COVID-19: results from an Italian cohort of 133 hypertensives","volume":"33","author":"Felice","year":"2020","journal-title":"Am J Hypertens"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","article-title":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension","volume":"9","author":"Meng","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.120.15143","article-title":"Effects of angiotensin II receptor blockers and ACE (Angiotensin-Converting Enzyme) inhibitors on virus infection, inflammatory status, and clinical outcomes in patients with COVID-19 and hypertension: a single-center retrospective study","volume":"76","author":"Yang","year":"2020","journal-title":"Hypertension (Dallas, Tex: 1979)"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jinf.2020.05.056","article-title":"COVID-19 patients with hypertension have more severity condition, and ACEI\/ARB treatment have no infulence on the clinical severity and outcome","volume":"81","author":"Hu","year":"2020","journal-title":"J Infect"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamacardio.2020.1624","article-title":"Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China","volume":"5","author":"Li","year":"2020","journal-title":"JAMA Cardiol"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","article-title":"Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19","volume":"126","author":"Zhang","year":"2020","journal-title":"Circ Res"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/eurheartj\/ehaa433","article-title":"Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study","volume":"41","author":"Gao","year":"2020","journal-title":"Eur Heart J"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"e01061-20","DOI":"10.1128\/AAC.01061-20","article-title":"A randomized clinical trial of the efficacy and safety of interferon beta-1a in treatment of severe COVID-19","volume":"64","author":"Davoudi-Monfared","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet (London, England)"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet (London, England)"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19\u2014preliminary report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"R32-20250504","article-title":"Remdesivir for Severe COVID-19 versus a Cohort receiving standard of care","author":"Olender","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R33-20250504","first-page":"105","article-title":"Efficacy and safety of lopinavir\/ritonavir or arbidol in adult patients with mild\/moderate COVID-19: an exploratory randomized controlled trial","volume":"1","author":"Li","year":"2020","journal-title":"Med (N Y)"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial","volume":"324","author":"Spinner","year":"2020","journal-title":"JAMA"},{"key":"R35-20250504","article-title":"AVIFAVIR for treatment of patients with moderate COVID-19: interim results of a phase II\/III multicenter randomized clinical trial","author":"Ivashchenko","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2012410","article-title":"Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19","volume":"382","author":"Geleris","year":"2020","journal-title":"N Engl J Med"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1056\/NEJMoa2019014","article-title":"Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19","volume":"383","author":"Cavalcanti","year":"2020","journal-title":"N Engl J Med"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"m1849","DOI":"10.1136\/bmj.m1849","article-title":"Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial","volume":"369","author":"Tang","year":"2020","journal-title":"BMJ"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"R40-20250504","article-title":"Compassionate use of hydroxychloroquine in clinical practice for patients with mild to severe Covid-19 in a French university hospital","author":"Paccoud","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1093\/jac\/dkaa332","article-title":"Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial","volume":"75","author":"Abbaspour Kasgari","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.4269\/ajtmh.20-0873","article-title":"Hydroxychloroquine in the treatment of COVID-19: a multicenter randomized controlled study","volume":"103","author":"Abd-Elsalam","year":"2020","journal-title":"Am J Trop Med Hyg"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(20)32013-4","article-title":"Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"396","author":"Group","year":"2020","journal-title":"Lancet (London, England)"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1038\/s41467-020-19056-6","article-title":"A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics","volume":"11","author":"Lyngbakken","year":"2020","journal-title":"Nat Commun"},{"key":"R45-20250504","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1093\/jac\/dkaa334","article-title":"Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial","volume":"75","author":"Sadeghi","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"R46-20250504","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1056\/NEJMoa2022926","article-title":"Effect of hydroxychloroquine in hospitalized patients with Covid-19","volume":"383","author":"Horby","year":"2020","journal-title":"N Engl J med"},{"key":"R47-20250504","first-page":"e2020102","article-title":"Efficacy and safety of sofosbuvir\/ledipasvir in treatment of patients with COVID-19; A randomized clinical trial","volume":"91","author":"Khalili","year":"2020","journal-title":"Acta Bio-med Atenei Parmensis"},{"key":"R48-20250504","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1001\/jama.2020.25864","article-title":"Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial","volume":"325","author":"Lopes","year":"2021","journal-title":"JAMA"},{"key":"R49-20250504","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2213-2600(20)30511-7","article-title":"Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"9","author":"Monk","year":"2021","journal-title":"Lancet Respir Med"},{"key":"R50-20250504","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed Antiviral Drugs for Covid-19\u2014interim WHO solidarity trial results","volume":"384","author":"Pan","year":"2021","journal-title":"N Engl J Med"},{"key":"R51-20250504","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1001\/jama.2020.22240","article-title":"Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19: a randomized clinical trial","volume":"324","author":"Self","year":"2020","journal-title":"JAMA"},{"key":"R52-20250504","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1007\/s11606-020-06146-w","article-title":"Chloroquine and hydroxychloroquine for the treatment of COVID-19: a systematic review and meta-analysis","volume":"35","author":"Elavarasi","year":"2020","journal-title":"J Gen Intern Med"},{"key":"R53-20250504","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ddr.21656","article-title":"Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics","volume":"81","author":"Gurwitz","year":"2020","journal-title":"Drug Dev Res"},{"key":"R54-20250504","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"R55-20250504","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41591-020-0888-2","article-title":"The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin","volume":"26","author":"Chorin","year":"2020","journal-title":"Nat Med"},{"key":"R56-20250504","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.hrthm.2020.05.014","article-title":"QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine\/azithromycin","volume":"17","author":"Chorin","year":"2020","journal-title":"Heart rhythm"},{"key":"R57-20250504","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S2213-2600(20)30071-0","article-title":"Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics","volume":"8","author":"Zhang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"R58-20250504","doi-asserted-by":"crossref","first-page":"104927","DOI":"10.1016\/j.phrs.2020.104927","article-title":"ACEI\/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and meta-analysis","volume":"158","author":"Zhang","year":"2020","journal-title":"Pharmacol Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025532","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:10:16Z","timestamp":1746324616000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025532"}},"subtitle":["A systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2021,4,23]]},"references-count":57,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000025532","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-89225\/v1","asserted-by":"object"}]},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,23]]},"assertion":[{"value":"2020-11-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}